Nam K-W, Kim C K, Kim T J, An S J, Demchuk A M, Kim Y, Jung S, Han M-K, Ko S-B, Yoon B-W
Department of Neurology, Seoul National University Hospital, Seoul, Korea.
Department of Neurology, Korea University Guro Hospital, Seoul, Korea.
Eur J Neurol. 2017 Jan;24(1):205-211. doi: 10.1111/ene.13184. Epub 2016 Oct 20.
The occurrence of stroke in cancer patients is caused by conventional vascular risk factors and cancer-specific mechanisms. However, cryptogenic stroke in patients with cancer was considered to be more related to cancer-specific hypercoagulability. In this study, we investigated the potential of the D-dimer level to serve as a predictor of early neurologic deterioration (END) in cryptogenic stroke patients with active cancer.
We recruited 109 cryptogenic stroke patients with active cancer within 72 h of symptom onset. We defined END as an increase of ≥1 point in the motor National Institutes of Health Stroke Scale (NIHSS) score or ≥2 points in the total NIHSS score within 72 h of admission. After adjusting for potential confounding factors in the multivariate analysis, we calculated the odds ratios (ORs) and confidence intervals (CIs) of D-dimer in the prediction of END.
Among 109 patients, END events were identified in 34 (31%) patients within 72 h. END was significantly associated with systemic metastasis, multiple vascular territory lesions on the initial magnetic resonance imaging (MRI), initial NIHSS score and D-dimer levels. In the multivariate analysis, the D-dimer level (adjusted OR, 1.11; 95% CI, 1.04-1.17; P < 0.01) and initial NIHSS score (adjusted OR, 1.08; 95% CI, 1.01-1.15; P = 0.03) predicted END after adjusting for potential confounding factors. In the subgroup analysis of 72 follow-up MRIs, D-dimer level was also correlated with new territory lesions on the follow-up MRI in a dose-dependent manner.
Ischemic stroke patients with active cancer and elevated D-dimer levels appear to be at increased risk for END recurrent thromboembolic stroke.
癌症患者中风的发生是由传统血管危险因素和癌症特异性机制引起的。然而,癌症患者的隐源性中风被认为与癌症特异性高凝状态关系更为密切。在本研究中,我们调查了D-二聚体水平作为活动性癌症的隐源性中风患者早期神经功能恶化(END)预测指标的可能性。
我们招募了109例症状发作72小时内的活动性癌症隐源性中风患者。我们将END定义为入院72小时内美国国立卫生研究院卒中量表(NIHSS)运动评分增加≥1分或总NIHSS评分增加≥2分。在多变量分析中对潜在混杂因素进行校正后,我们计算了D-二聚体预测END的比值比(OR)和置信区间(CI)。
109例患者中,34例(31%)在72小时内发生END事件。END与全身转移、初始磁共振成像(MRI)上的多个血管区域病变、初始NIHSS评分和D-二聚体水平显著相关。在多变量分析中,校正潜在混杂因素后,D-二聚体水平(校正OR,1.11;95%CI,1.04-1.17;P<0.01)和初始NIHSS评分(校正OR,1.08;95%CI,1.01-1.15;P=0.03)可预测END。在72次随访MRI的亚组分析中,D-二聚体水平也与随访MRI上新发区域病变呈剂量依赖性相关。
活动性癌症且D-二聚体水平升高的缺血性中风患者发生END复发性血栓栓塞性中风的风险似乎增加。